JP2013520512A - 低い反応成分比を用いて、ｐｅｇ−ヘモグロビン結合体を調製するための方法 - Google Patents

低い反応成分比を用いて、ｐｅｇ−ヘモグロビン結合体を調製するための方法 Download PDF

Info

Publication number
JP2013520512A
JP2013520512A JP2012555105A JP2012555105A JP2013520512A JP 2013520512 A JP2013520512 A JP 2013520512A JP 2012555105 A JP2012555105 A JP 2012555105A JP 2012555105 A JP2012555105 A JP 2012555105A JP 2013520512 A JP2013520512 A JP 2013520512A
Authority
JP
Japan
Prior art keywords
peg
concentration
mal
conjugate
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012555105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520512A5 (cg-RX-API-DMAC10.html
Inventor
アショク マラバリ，
キム ディー． バンデグリフ，
Original Assignee
サンガート， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンガート， インコーポレイテッド filed Critical サンガート， インコーポレイテッド
Publication of JP2013520512A publication Critical patent/JP2013520512A/ja
Publication of JP2013520512A5 publication Critical patent/JP2013520512A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012555105A 2010-02-25 2011-02-23 低い反応成分比を用いて、ｐｅｇ−ヘモグロビン結合体を調製するための方法 Pending JP2013520512A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30823810P 2010-02-25 2010-02-25
US61/308,238 2010-02-25
PCT/US2011/025888 WO2011106396A1 (en) 2010-02-25 2011-02-23 Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios

Publications (2)

Publication Number Publication Date
JP2013520512A true JP2013520512A (ja) 2013-06-06
JP2013520512A5 JP2013520512A5 (cg-RX-API-DMAC10.html) 2013-07-18

Family

ID=44507180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012555105A Pending JP2013520512A (ja) 2010-02-25 2011-02-23 低い反応成分比を用いて、ｐｅｇ−ヘモグロビン結合体を調製するための方法

Country Status (8)

Country Link
US (1) US9493616B2 (cg-RX-API-DMAC10.html)
EP (1) EP2539715B1 (cg-RX-API-DMAC10.html)
JP (1) JP2013520512A (cg-RX-API-DMAC10.html)
KR (1) KR20130067243A (cg-RX-API-DMAC10.html)
CN (1) CN102859364A (cg-RX-API-DMAC10.html)
AU (2) AU2011220885A1 (cg-RX-API-DMAC10.html)
CA (1) CA2791122C (cg-RX-API-DMAC10.html)
WO (1) WO2011106396A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109731098A (zh) 2012-03-29 2019-05-10 桑加特公司 双阿司匹林交联聚乙二醇化血红蛋白
WO2013151776A1 (en) 2012-04-03 2013-10-10 Sangart, Inc. Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING
US11857605B2 (en) 2021-03-01 2024-01-02 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
US20250064724A1 (en) * 2021-11-18 2025-02-27 Virginia Commonwealth University Modular field-stable bio-artificial blood substitute
WO2025219465A1 (en) * 2024-04-19 2025-10-23 Danmarks Tekniske Universitet Hemoglobin-based oxygen carrier

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515225A (ja) * 2002-01-11 2005-05-26 サンガート， インコーポレイテッド 高酸素親和性改変ヘモグロビンを含む、酸素輸送のための方法および組成物
US20050159339A1 (en) * 2002-03-25 2005-07-21 Acharya Seetharama A. Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
JP2006514652A (ja) * 2002-12-23 2006-05-11 イェシバ・ユニバーシティ 修飾ヘモグロビンおよびこれの調製方法
US20060111275A1 (en) * 2001-07-19 2006-05-25 Acharya Seetharama A Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2161086B2 (de) 1971-12-09 1975-04-24 Anton Cramer & Co, 4402 Greven Daunen- und federndichtes Gewebe
DE2449885C3 (de) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5449759A (en) 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5585484A (en) * 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US6054427A (en) 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
EP1121165A1 (en) * 1998-10-15 2001-08-08 Sangart, Inc. Method for production of stroma-free hemoglobin
CN1219811C (zh) * 2003-01-22 2005-09-21 中国科学院过程工程研究所 带单甲氧基聚乙二醇长尾的蛋白质修饰剂及制法和用途
CN1997666A (zh) * 2003-02-26 2007-07-11 印特缪恩股份有限公司 聚乙二醇修饰的干扰素组合物及其使用方法
DE602005023191D1 (de) 2004-08-31 2010-10-07 Sangart Inc Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen
EP1863503B1 (en) 2005-03-07 2019-05-22 Sangart, Inc. Composition for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
US8697645B2 (en) * 2007-03-13 2014-04-15 Albert Einstein College Of Medicine Of Yeshiva University Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders
US8021858B2 (en) 2008-09-22 2011-09-20 Sangart, Inc. Method for making polyalkylene oxide modified hemoglobin
US20130041134A1 (en) 2009-11-05 2013-02-14 Sangart ,Inc. Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060111275A1 (en) * 2001-07-19 2006-05-25 Acharya Seetharama A Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols
JP2005515225A (ja) * 2002-01-11 2005-05-26 サンガート， インコーポレイテッド 高酸素親和性改変ヘモグロビンを含む、酸素輸送のための方法および組成物
US20050159339A1 (en) * 2002-03-25 2005-07-21 Acharya Seetharama A. Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
JP2006514652A (ja) * 2002-12-23 2006-05-11 イェシバ・ユニバーシティ 修飾ヘモグロビンおよびこれの調製方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014027378; Ｒｏｂｅｒｔｏ　ＩＡＦＥＬＩＣＥ　ｅｔ　ａｌ: Ｂｉｏｃｈｅｍ．　Ｊ． ｖｏｌ．４０３，　ｎｏ．１, 2007, ｐ．１８９-１９６ *

Also Published As

Publication number Publication date
CA2791122C (en) 2019-08-27
EP2539715A4 (en) 2016-03-02
KR20130067243A (ko) 2013-06-21
EP2539715B1 (en) 2021-12-22
EP2539715A1 (en) 2013-01-02
WO2011106396A1 (en) 2011-09-01
AU2011220885A1 (en) 2012-09-06
US20130217860A1 (en) 2013-08-22
AU2017232073B2 (en) 2019-01-31
AU2017232073A1 (en) 2017-10-12
CN102859364A (zh) 2013-01-02
CA2791122A1 (en) 2011-09-01
US9493616B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
AU2017232073B2 (en) Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios
JP6668515B2 (ja) ジアスピリン架橋ｐｅｇヘモグロビン
JP6657070B2 (ja) ポリアルキレンオキシド吉草酸ヘモグロビン接合体
US8609815B2 (en) Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
US8021858B2 (en) Method for making polyalkylene oxide modified hemoglobin
HK1177255A (en) Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
US20120282236A1 (en) Method of delivering oxygen using peg-hemoglobin conjugates with enhanced nitrite reductase activity
HK40008755A (en) Diaspirin crosslinked pegylated hemoglobin
HK1219053B (en) Polyalkylene oxide valerate hemoglobin conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141201